FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2081872783> ?p ?o ?g. }

• W2081872783 endingPage "554" @default.
• W2081872783 startingPage "545" @default.
• W2081872783 abstract "PurposeAKB-9778 is a small-molecule competitive inhibitor of vascular endothelial-protein tyrosine phosphatase (VE-PTP) that promotes Tie2 activation and reduces vascular leakage and neovascularization in mouse models. The purpose of this study was to test the safety, tolerability, pharmacokinetics, and biological activity of AKB-9778 in patients with diabetic macular edema (DME).DesignOpen-label, dose-escalation clinical trial.ParticipantsFour dose cohorts of 6 patients with DME self-administered subcutaneous injections of 5 mg, 15 mg, 22.5 mg, or 30 mg AKB-9778 twice daily for 4 weeks.MethodsPatients were seen weekly during a 4-week treatment period for safety assessments, best-corrected visual acuity (BCVA) assessment by Early Treatment Diabetic Retinopathy Study protocol, and measurement of central subfield thickness (CST) by spectral-domain optical coherence tomography. Additional safety assessments were performed at 6, 8, and 12 weeks.Main Outcome MeasuresSafety assessments, change from baseline BCVA, and change from baseline CST.ResultsAll doses were well tolerated. A modest, transient reduction in blood pressure and adverse events consistent with vasodilatory activity of AKB-9778 emerged at doses of 22.5 mg or more twice daily. At the week 4 primary end point, BCVA improved 5 letters or more from baseline in 13 of the 18 patients receiving 15 mg or more twice daily; 1 patient improved by 10 to 15 letters, and 2 patients improved by more than 15 letters. Among 18 patients receiving 15 mg or more twice daily, CST decreased by more than 100 μm in 5 patients and by 50 to 100 μm in 2 patients. There was a significant correlation between reduction in CST and improvement in BCVA.ConclusionsNo safety concerns were identified after systemic administration of AKB-9778 for 4 weeks in patients with DME, and doses of 15 mg or more twice daily reduced macular edema and improved vision in some patients. This is a preliminary demonstration of clinical safety and efficacy of a VE-PTP inhibitor and Tie2 activator. AKB-9778 is a small-molecule competitive inhibitor of vascular endothelial-protein tyrosine phosphatase (VE-PTP) that promotes Tie2 activation and reduces vascular leakage and neovascularization in mouse models. The purpose of this study was to test the safety, tolerability, pharmacokinetics, and biological activity of AKB-9778 in patients with diabetic macular edema (DME). Open-label, dose-escalation clinical trial. Four dose cohorts of 6 patients with DME self-administered subcutaneous injections of 5 mg, 15 mg, 22.5 mg, or 30 mg AKB-9778 twice daily for 4 weeks. Patients were seen weekly during a 4-week treatment period for safety assessments, best-corrected visual acuity (BCVA) assessment by Early Treatment Diabetic Retinopathy Study protocol, and measurement of central subfield thickness (CST) by spectral-domain optical coherence tomography. Additional safety assessments were performed at 6, 8, and 12 weeks. Safety assessments, change from baseline BCVA, and change from baseline CST. All doses were well tolerated. A modest, transient reduction in blood pressure and adverse events consistent with vasodilatory activity of AKB-9778 emerged at doses of 22.5 mg or more twice daily. At the week 4 primary end point, BCVA improved 5 letters or more from baseline in 13 of the 18 patients receiving 15 mg or more twice daily; 1 patient improved by 10 to 15 letters, and 2 patients improved by more than 15 letters. Among 18 patients receiving 15 mg or more twice daily, CST decreased by more than 100 μm in 5 patients and by 50 to 100 μm in 2 patients. There was a significant correlation between reduction in CST and improvement in BCVA. No safety concerns were identified after systemic administration of AKB-9778 for 4 weeks in patients with DME, and doses of 15 mg or more twice daily reduced macular edema and improved vision in some patients. This is a preliminary demonstration of clinical safety and efficacy of a VE-PTP inhibitor and Tie2 activator." @default.
• W2081872783 created "2016-06-24" @default.
• W2081872783 creator A5001513569 @default.
• W2081872783 creator A5004807592 @default.
• W2081872783 creator A5016039997 @default.
• W2081872783 creator A5017209241 @default.
• W2081872783 creator A5021907714 @default.
• W2081872783 creator A5028848967 @default.
• W2081872783 creator A5051484351 @default.
• W2081872783 creator A5054285667 @default.
• W2081872783 creator A5058044536 @default.
• W2081872783 creator A5085965174 @default.
• W2081872783 creator A5091343114 @default.
• W2081872783 date "2015-03-01" @default.
• W2081872783 modified "2023-10-03" @default.
• W2081872783 title "Treatment of Diabetic Macular Edema with an Inhibitor of Vascular Endothelial-Protein Tyrosine Phosphatase That Activates Tie2" @default.
• W2081872783 cites W1486264823 @default.
• W2081872783 cites W1496977463 @default.
• W2081872783 cites W1598900543 @default.
• W2081872783 cites W1971968805 @default.
• W2081872783 cites W1976988821 @default.
• W2081872783 cites W1984205014 @default.
• W2081872783 cites W1985788023 @default.
• W2081872783 cites W1986448979 @default.
• W2081872783 cites W1991409385 @default.
• W2081872783 cites W2003839328 @default.
• W2081872783 cites W2006355752 @default.
• W2081872783 cites W2010000693 @default.
• W2081872783 cites W2016479907 @default.
• W2081872783 cites W2022886290 @default.
• W2081872783 cites W2043463860 @default.
• W2081872783 cites W2049624292 @default.
• W2081872783 cites W2055237834 @default.
• W2081872783 cites W2066888615 @default.
• W2081872783 cites W2081930185 @default.
• W2081872783 cites W2084452119 @default.
• W2081872783 cites W2091839917 @default.
• W2081872783 cites W2097443918 @default.
• W2081872783 cites W2103965396 @default.
• W2081872783 cites W2114147340 @default.
• W2081872783 cites W2121109442 @default.
• W2081872783 cites W2126945510 @default.
• W2081872783 cites W2128154767 @default.
• W2081872783 cites W2128210855 @default.
• W2081872783 cites W2128726320 @default.
• W2081872783 cites W2147358575 @default.
• W2081872783 cites W2148472151 @default.
• W2081872783 cites W2152215024 @default.
• W2081872783 cites W2156799887 @default.
• W2081872783 cites W2165256339 @default.
• W2081872783 cites W2616361514 @default.
• W2081872783 cites W4233230329 @default.
• W2081872783 doi "https://doi.org/10.1016/j.ophtha.2014.09.023" @default.
• W2081872783 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/25439435" @default.
• W2081872783 hasPublicationYear "2015" @default.
• W2081872783 type Work @default.
• W2081872783 sameAs 2081872783 @default.
• W2081872783 citedByCount "72" @default.
• W2081872783 countsByYear W20818727832015 @default.
• W2081872783 countsByYear W20818727832016 @default.
• W2081872783 countsByYear W20818727832017 @default.
• W2081872783 countsByYear W20818727832018 @default.
• W2081872783 countsByYear W20818727832019 @default.
• W2081872783 countsByYear W20818727832020 @default.
• W2081872783 countsByYear W20818727832021 @default.
• W2081872783 countsByYear W20818727832022 @default.
• W2081872783 countsByYear W20818727832023 @default.
• W2081872783 crossrefType "journal-article" @default.
• W2081872783 hasAuthorship W2081872783A5001513569 @default.
• W2081872783 hasAuthorship W2081872783A5004807592 @default.
• W2081872783 hasAuthorship W2081872783A5016039997 @default.
• W2081872783 hasAuthorship W2081872783A5017209241 @default.
• W2081872783 hasAuthorship W2081872783A5021907714 @default.
• W2081872783 hasAuthorship W2081872783A5028848967 @default.
• W2081872783 hasAuthorship W2081872783A5051484351 @default.
• W2081872783 hasAuthorship W2081872783A5054285667 @default.
• W2081872783 hasAuthorship W2081872783A5058044536 @default.
• W2081872783 hasAuthorship W2081872783A5085965174 @default.
• W2081872783 hasAuthorship W2081872783A5091343114 @default.
• W2081872783 hasBestOaLocation W20818727831 @default.
• W2081872783 hasConcept C118487528 @default.
• W2081872783 hasConcept C126322002 @default.
• W2081872783 hasConcept C126894567 @default.
• W2081872783 hasConcept C134018914 @default.
• W2081872783 hasConcept C197934379 @default.
• W2081872783 hasConcept C203092338 @default.
• W2081872783 hasConcept C2778257484 @default.
• W2081872783 hasConcept C2778375690 @default.
• W2081872783 hasConcept C2779829184 @default.
• W2081872783 hasConcept C2780347916 @default.
• W2081872783 hasConcept C2780886150 @default.
• W2081872783 hasConcept C2781092963 @default.
• W2081872783 hasConcept C535046627 @default.
• W2081872783 hasConcept C555293320 @default.
• W2081872783 hasConcept C71924100 @default.
• W2081872783 hasConceptScore W2081872783C118487528 @default.
• W2081872783 hasConceptScore W2081872783C126322002 @default.
• W2081872783 hasConceptScore W2081872783C126894567 @default.

• next